Professor Issac Adewole, M.D., the newly appointed Minister of Health for Nigeria, is an early proponent of the benefits of using the LuViva® Advanced Cervical Scan from Guided Therapeutics, Inc. (OTCQB: GTHP) and conducted the first clinical trial of the product in Africa.
When presenting study results to the Society of Gynecology and Obstetrics of Nigeria in November 2014, Minister Adewole said, “These results are encouraging and demonstrate the value of LuViva as a means to detect cervical disease, even in the absence of a positive human papillomavirus result, while also providing a means to reduce unnecessary additional testing. In addition to the accuracy displayed in the study, LuViva is painless and results are immediate - important attributes for the patient and healthcare provider, particularly in rural communities.”
“Congratulations to Minister Adewole on his appointment to this very important leadership position,” said Gene Cartwright, CEO and President of Guided Therapeutics, Inc. “We look forward to working with Minister Adewole and the Ministry to advance the state of women’s health in Nigeria and all of Africa.”
Before being named Minister of Health, Professor Adewole served as the Vice Chancellor of the University of Ibadan and former President of the African Organisation for Research and Training in Cancer. Prior to his appointment as the 11th substantive Vice Chancellor of the University, he served as Provost, College of Medicine, University of Ibadan, the largest and oldest Medical school in Nigeria. His research interest is in the area of Human papillomavirus, HIV and Gynecologic oncology, a specialized field of medicine that focuses on cancers of the female reproductive system, including ovarian cancer, uterine cancer, vaginal cancer, cervical cancer, and vulvar cancer. Read more about Minister Adewole here.
A 100-patient study led by Professor Adewole conducted at University Teaching Hospital in Ibadan, Nigeria, concluded that LuViva was able to detect 100% of serious pre-cancer (Cervical intraepithelial neoplasia 2+, CIN2+) while identifying, and thereby eliminating, up to 40% of false positive results, or women who were actually disease free, from further testing. These results are consistent with other published studies conducted in North America. Three of the CIN2+ cases correctly identified by LuViva tested negative for HPV at the time of the study. View the study results here.
Worldwide, the market for cervical cancer screening and diagnostics, as currently practiced using cytology (Pap test) for primary screening, is estimated at $6 billion and is projected to grow to almost $9 billion by 2020. Worldwide there are about 2.6 billion women aged 15 years and older who are at risk of developing cervical cancer.
About LuViva® Advanced Cervical Scan
LuViva is a technologically advanced diagnostic device that scans the cervix with light and uses spectroscopy to measure how light interacts with the cervical tissue. Spectroscopy identifies chemical and structural indicators of precancer that may be below the surface of the cervix or misdiagnosed as benign. This technique is called biophotonics. Unlike Pap, HPV tests or biopsies, LuViva does not require laboratory analysis or a tissue sample, and is designed to provide results immediately, which may result in eliminating costly, painful and unnecessary additional testing. LuViva is intended for use with women who have undergone initial screening and are called back for follow up with a colposcopy examination, which in many cases, involves taking a biopsy of the cervix. It has also been used in clinical studies in Turkey and Nigeria as a means to screen women for cervical cancer where the availability of infrastructure necessary for Pap and HPV testing is restricted. The device is used in conjunction with the LuViva® Cervical Guide single-use patient interface and calibration disposable.
About Guided Therapeutics
Guided Therapeutics, Inc. (OTCQB: GTHP) is the maker of a rapid and painless testing platform based on its patented biophotonic technology that utilizes light for the early detection of disease at the cellular level. The Company’s first product is the LuViva® Advanced Cervical Scan, a non-invasive device used to detect cervical disease instantly and at the point of care. In a multi-center clinical trial, with women at risk for cervical disease, the technology was able to detect cervical cancer up to two years earlier than conventional modalities, according to published reports. For more information, visit: www.guidedinc.com.
The Guided Therapeutics LuViva® Advanced Cervical Scan is an investigational device and is limited by federal law to investigational use in the U.S. LuViva, the wave logo and "Early detection, better outcomes" are registered trademarks owned by Guided Therapeutics, Inc.
Forward-Looking Statements Disclaimer: A number of the matters and subject areas discussed in this news release that are not historical or current facts deal with potential future circumstances and developments. The discussion of such matters and subject areas is qualified by the inherent risks and uncertainties surrounding future expectations generally and also may materially differ from Guided Therapeutics’ actual future experience involving any of or more of such matters and subject areas. Such risks and uncertainties include those related to the early stage of products in development, the uncertainty of market acceptance of products, the uncertainty of development or effectiveness of distribution channels, the intense competition in the medical device industry, the sufficiency of capital raised in our prior financings and our ability to realize their expected benefits, the uncertainty of future capital to develop products or continue as a going concern, the uncertainty of regulatory approval of products, and the dependence on licensed intellectual property, as well as those that are more fully described from time to time under the heading “Risk Factors” in Guided Therapeutics’ reports filed with the SEC, including Guided Therapeutics’ Annual Report on Form 10-K for the fiscal year ended December 31, 2014 and subsequent filings.
Robert Haag, 866-976-4784
Bill Wells, 770-242-8723